Frontiers in pharmacology · 2026
Modified gegen qinlian decoction ameliorates Veillonella parvula-exacerbated ulcerative colitis via restoration of intestinal mucosal barrier function.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
She Meiling, Dai Xinyi, Wang Xintong, Wang Zheng, Zhang Jiaqi, Shi Zhuo, Peng Ying, Li Xiaobo, Chen Ting, Tang Xudong
Аннотация
INTRODUCTION: Ulcerative colitis (UC) is being increasingly connected to the pathogen Veillonella parvula (V. parvula). Modified Gegen Qinlian Decoction (MGQD), a traditional Chinese medicine therapy, is used to treat UC. However, the underlying mechanism by which V. parvula exacerbates UC and whether MGQD can alleviate it is unknown.
METHODS: MGQD therapy was tested on pathogen-free and pseudo-germ-free mice infected with V. parvula. Colitis severity was determined by disease activity index, colon length, and histology. Transmission electron microscopy, Western blot, immunofluorescence, and immunohistochemistry were used to assess the integrity of the intestinal mucosal barrier. In vitro, mouse colonic organoids were utilized to examine the effects of baicalin and puerarin on inflammation-induced downregulation of Muc2 and ZO-1.
RESULTS: MGQD therapy dramatically reduced the severity of colitis in both mouse models. MGQD restored the integrity of the mucus and mechanical barriers. Furthermore, baicalin and puerarin reduced inflammation-induced downregulation of Muc2 and ZO-1 in mouse colonic organoids.
DISCUSSION: These findings demonstrate that MGQD alleviates intestinal barrier dysfunction caused by V. parvula, providing novel mechanistic insight for the management of chronic colitis.
METHODS: MGQD therapy was tested on pathogen-free and pseudo-germ-free mice infected with V. parvula. Colitis severity was determined by disease activity index, colon length, and histology. Transmission electron microscopy, Western blot, immunofluorescence, and immunohistochemistry were used to assess the integrity of the intestinal mucosal barrier. In vitro, mouse colonic organoids were utilized to examine the effects of baicalin and puerarin on inflammation-induced downregulation of Muc2 and ZO-1.
RESULTS: MGQD therapy dramatically reduced the severity of colitis in both mouse models. MGQD restored the integrity of the mucus and mechanical barriers. Furthermore, baicalin and puerarin reduced inflammation-induced downregulation of Muc2 and ZO-1 in mouse colonic organoids.
DISCUSSION: These findings demonstrate that MGQD alleviates intestinal barrier dysfunction caused by V. parvula, providing novel mechanistic insight for the management of chronic colitis.